Background and Aims: Inflammatory bowel disease [IBD] is associated with a 1.5-to 3-fold increased risk of venous thromboembolism [VTE] events. The aim of this study was to determine the risk of VTE in IBD as a complication of systemic corticosteroids and anti-tumour necrosis factor alpha [TNFα] therapies. Methods: A systematic review and meta-analysis was conducted, which conforms to the Preferred Reporting Items for Systematic Reviews and Meta-analyses [PRISMA] statement. PubMed, EMBASE, Cochrane Library and Web of Science were searched for English-language studies published from inception inclusive of 15 April 2017. The population-intervention-comparisonoutcome [PICO] format and statistically the random-effects and fixed-effect models were used to compare VTE risk during steroid and anti-TNFα treatment. Quality of the included studies was assessed using the Newcastle-Ottawa scale. The PROSPERO registration number is 42017070084. Results: We identified 817 records, of which eight observational studies, involving 58 518 IBD patients, were eligible for quantitative synthesis. In total, 3260 thromboembolic events occurred. Systemic corticosteroids were associated with a significantly higher rate of VTE complication in IBD patients as compared to IBD patients without steroid medication (odds ratio [OR]: 2.202; 95% confidence interval [CI]: 1.698-2.856, p < 0.001). In contrast, treatment with anti-TNFα agents resulted in a 5-fold decreased risk of VTE compared to steroid medication [OR: 0.267; 95% CI: 0.106-0.674, p = 0.005]. Conclusion: VTE risk should be carefully assessed and considered when deciding between anti-TNFα and steroids in the management of severe flare-ups. Thromboprophylaxis guidelines should be followed, no matter the therapy choice.
Introduction
Venous thromboembolism [VTE] , mainly deep vein thrombosis [DVT] and pulmonary embolism [PE] , is one of the most common types of cardiovascular disorders. VTE is associated with several adverse consequences including increased morbidity and mortality. 1 The incidence rate of the first VTE event is approximately 1:1000/ year in the United States. 2, 3 Despite adequate anticoagulant therapy, recurrent VTE occurs frequently in the first few months. 2, 3 The long-term complications of VTE, such as post-thrombotic syndrome or chronic thromboembolic pulmonary hypertension, also significantly reduce the patient's quality of life. 4 The risk of VTE has been widely examined in inflammatory bowel disease [IBD] patients, including ulcerative colitis [UC] and Crohn's disease [CD] . 5 Several population-based cohort studies have shown that IBD patients have a 1.5-to 3-fold higher risk of developing VTE compared to non-IBD controls. [6] [7] [8] [9] [10] In a recent meta-analysis, Yuhara et al. estimated the relative risk [RR] for DVT and PE among IBD patients to be 2.20 (95% confidence interval [CI]: 1.83-2.65). 8 The risk of VTE in IBD patients is increased regardless of the diagnosis [UC: RR = 2.57, 95% CI: 2.02-3.28; CD: RR = 2.12, 95% CI: 1. 40-3.20] 8 and sex. 5, 8, 10 The pathogenesis of VTE in IBD patients is multifactorial and not completely understood. Inherited risk factors for VTE, such as factor V Leiden, factor II prothrombin, factor XIII, plasminogen activator inhibitor type 1, methylenetetrahydrofolate reductase gene polymorphism, antithrombin deficiency, protein C/protein S deficiencies, hyperhomocysteinaemia and dysfibrinogenaemia, also play a role in IBD-VTE. However, these hereditary risk factors contribute equally to VTE in patients with IBD compared to VTE in the general population. 11, 12 Indeed, acquired risk factors appear the most relevant ones in the development of VTE in IBD patients. 13 The majority of VTE occurs during the acute flare-up of the disease [hazard risk (HR) = 8.4, 95% CI: 5.5-12.8], compared with periods of clinical remission [HR = 2.1, 95% CI: 1.6-2.9]. 14, 15 Moreover, hospitalized IBD patients have higher rates of VTE than non-IBD hospitalized patients. 6, 14, [16] [17] [18] [19] [20] The well-established, non-specific acquired VTE risk factors (e.g. smoking, oral contraceptives, immobilization, central venous catheters, pregnancy and dehydration) might also provoke the development of VTE in IBD patients. 13, 15 To date, most studies have suggested that IBD is associated with prothrombotic abnormalities, including activation of the coagulation cascade, downregulation of its natural inhibitors and impairment of fibrinolysis. 21 Increased platelet count and dysfunction of the endothelium also contribute to VTE in IBD patients. 13 Some drugs used in IBD treatment were found to influence the haemostatic system. Among them, glucocorticoids are potent anti-inflammatory drugs widely used for the induction of remission during the acute phase of IBD. Experimental studies have shown that glucocorticoid treatment alone increases the levels of clotting factors and fibrinogen. 22 However, conflicting data exist regarding the association between coagulation and anti-TNFα treatment. Anti-TNFα agents can be used for induction and maintenance of remission in IBD. Increased TNFα levels in IBD seem to be a disease-specific risk factor for accelerated thrombus formation, and thus therapies antagonizing TNFα potentially decrease the risk for thromboembolic complications.
In a prospective observational cohort study in rheumatoid arthritis patients, use of anti-TNFα therapy was not associated with an increased risk of VTE. 23 In contrast to these findings, retrospective data from the French adverse drug reporting system suggested that VTE could be favoured by TNFα blockers. 24 Moreover, the formation of antiphospholipid antibodies during anti-TNFα treatment could promote hypercoagulation state in IBD patients. 25 Therapy-specific risk factors for IBD, such as the effects of steroid treatment and anti-TNFα treatment on VTE complications, have not been compared in previous meta-analyses. Therefore, our primary objective was to determine whether corticosteroid and anti-TNFα treatment carry an increased risk of venous thromboembolic complication in IBD flare-ups.
Methods
The protocol of this systematic review and meta-analysis is in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses [PRISMA] statement 26 
Eligibility criteria
Observational studies evaluating venous thromboembolic complications in patients with CD or UC requiring systemic corticosteroid or anti-TNFα therapy for flare-up of their disease were eligible for inclusion [ Table 1 ]. In our meta-analysis, patients were divided into two subgroups, as follows: (A) steroid therapy vs treatment without steroids and (B) anti-TNFα vs steroid treatment. First, we selected studies that reported data on steroid vs no steroid treatment in IBD patients during hospitalization, within 3 months after discharge 28 or in a postoperative setting. 20, 29, 30 Publications for which data were retrieved from national registries 31 or inception cohorts 32 were also included. In the second part of the analysis we examined correlations between studies investigating VTE complications on anti-TNFα treatment or steroid therapy for active disease. 28, 33, 34 Studies evaluating only paediatric patients [age < 18 years] were excluded. The following data were extracted from each included study: first author, year of publication, study design [prospective/retrospective and single-centre/multi-centre study], inclusion period, type of disease [CD or UC], country/geographical region of origin, study population, age range of study subjects, number of total IBD patients [subdivided into CD and UC groups], number of VTE events in IBD cases, and number of VTE events in IBD cases [controls] . The number of patients on steroid or TNFα inhibitor therapy was also recorded when it was available.
Search strategy

Study quality and risk of bias
The quality and biases of the studies included in the analysis were assessed using a modified Newcastle-Ottawa scale [NOS] for observational studies in meta-analyses. 35 Two reviewers [NF and PS] independently evaluated the quality of each included study, discrepancies were discussed and if consensus was not reached, a third reviewer was consulted [PH] . The NOS scale for cohort studies contains eight items covering three main domains [selection, comparability and outcome]. A study can be awarded a maximum of one star for each numbered item; on the other hand, a maximum of two stars can be given for comparability. Each item was rated as 'high risk' [zero stars], 'low risk' [one star] or 'unclear risk' [zero stars] corresponding to the definitions [Supplementary Table S3 ]. The item 'Demonstration that outcome of interest was not present at start of study' was not applicable because patients not exhibiting symptoms for VTE are not routinely tested in daily clinical practice. The last item in the outcome domain ['Adequacy of follow-up of cohorts'] was also removed from the tool because it is uninterpretable in retrospective studies.
Outcome assessment
The main outcome studied in this meta-analysis was the chance of VTE occurrence in two patient groups: (A) steroid vs no steroid treatment group, (B) anti-TNFα vs steroid treatment group. If there were not sufficient data published to assess the risk for VTE in IBD patients [e.g. no OR calculated or insufficient data for calculating OR], the article was excluded from the meta-analysis.
Statistical data analysis
For our outcome data of VTE events from the individual studies we extracted the OR and its 95% CI. OR or CI were calculated from the original data, when these parameters were not specified. 28, 31 In the study of Ananthakrishnan et al., 33 we used HR rather than converting it to OR. In the literature, there are methods for the conversion of HR to OR, 36, 37 but this transaction carries bias. Only three articles were identified where the TNFα inhibitor and the steroid treatment were compared. A meta-analysis including few studies bears greater publication bias and we did not want to increase the chance for errors with this conversion. The follow-up times in the studies were nearly the same, and in these cases, the HR can be handled as OR in a forest plot according to Cochran's Handbook [Chapter 9]. 38 The meta-analytic calculations were performed by Comprehensive MetaAnalysis software [Version3, Biostat Inc.]. Heterogeneity was tested by using Cochrane's Q and I 2 statistics, where I 2 = 100% × (Q−df)/Q and represents the magnitude of the heterogeneity [moderate: 30-60%, substantial: 50-90%, considerable: 75-100%]. In our study, as seen in Figure 2A , Q = 18.166, p = 0.006 and I 2 = 66.971, and thus we applied the random-effects model, using the DerSimonian-Laird method. 39 In Figure 2B Publication bias was evaluated by visual assessment of the funnel plot because only six studies were included in our meta-analysis [subgroup A]. Tests for funnel plot asymmetry should be used only when there are at least ten studies included in the meta-analysis, because the power of the test is too low to distinguish chance from real asymmetry when the number of studies is less than ten. 38 
Results
Literature search results
Our systematic literature search strategy identified 817 potentially relevant records [PRISMA flow diagram; Figure 1 ]. After removal of duplicates and screening of title and abstract, 21 papers remained for full-text evaluation. Following the revision of the eligible studies, 12 additional ones were excluded: studies without OR or extractable data [n = 3], case reports [n = 3], reviews [n = 4], no matching control group [n = 2, e.g. non-IBD VTE controls]. One additional study was excluded from the A-subgroup analysis because of the lack of matching controls in the 'no steroid' group, although the data of the study were eligible for B-subgroup assessment. 34 Finally, the remaining eight studies, published between 2012 and 2016, fulfilled the selection criteria [ Table 1 ].
Study characteristics
Eight studies were included in this meta-analysis. Of these, six reported on VTE complication in IBD patients during steroid treatment [A-group] 20,28-32 and three on anti-TNFα therapy [B-group]. 28, 33, 34 OR was calculated in CD in one study, 29 and in UC in two studies, 30, 31 while the others reported combined CD + UC results 28, [32] [33] [34] ; only the publication from Nguyen et al. 20 assessed VTE risk in CD and UC separately. Since the risk for VTE in IBD patients is equally increased in both CD and UC, the results of the different studies can be evaluated together. Most of the patients included in the studies underwent an IBD-related surgery, were hospitalized and were followed during hospitalization or up to 3 months after discharge. 20, [28] [29] [30] 33 Only a few articles reported outcomes retrieved from registries. 31, 32, 34 All of the studies were retrospective, including two single-centre and six multicentre analyses. The individual study characteristics are provided in Tables 2 and 3 .
Risk of VTE in IBD patients treated with corticosteroids
Six studies assessed VTE risk in CD and UC patients treated or not with systemic corticosteroids. 20, [28] [29] [30] [31] [32] 
Risk of VTE in IBD patients treated with anti-TNFα
Only three studies assessed VTE risk in IBD patients treated with anti-TNFα compared to IBD patients treated with systemic corticosteroids. 28, 33, 34 A total of 18 435 IBD patients were analysed and 399 [2.16%] VTE events were reported. Two of three individual studies had an OR < 1.0 attaining statistical significance [p < 0.05]. 28, 34 There was a significantly lower rate of VTE complications in anti-TNFα 
Risk of bias assessment
Overall NOS scores of the included studies in our meta-analysis ranged from 5 to 6 [Supplementary Table S4] . Since all studies were large IBD cohorts with a corresponding non-exposed control group, they carried a low risk of bias in terms of representativeness, and also in terms of ascertainment of exposure. Comparability received the lowest count of stars: only 22% of the studies were rated as having low risk. All studies provided a clear definition of the diagnosis of VTE, including the details of the confirmation based on imaging techniques. Some studies used the international disease codes for VTE diagnosis. All patients were followed up for at least 3 months, thereby fulfilling the corresponding NOS item. Risk of bias of the included studies is summarized in Figures 4 and 5 . The funnel plot in Figure 6 shows slight bias potentially as a consequence of a 'small-study effect', suggesting that smaller trials with no or moderate treatment effect may have remained unpublished. In our meta-analysis, the included articles are large cohort studies, except for that of Singh et al., 31 where the steroid-user group included 80 patients. This study may have overestimated the risk of VTE, as is well known for small trials.
Discussion
Our meta-analysis evaluated pooled data from all currently available observational studies evaluating the risk of VTE in IBD as a complication of steroid and anti-TNFα therapies. Our results indicated that treatment with anti-TNFα was associated with a significantly lower risk of thromboembolic events in IBD patients [OR: 0.267; 95% CI: 0.106-0.674, p = 0.005] compared to steroid therapy. In contrast, VTE in IBD patients using systemic corticosteroids occurs twice as often as in the control group of IBD patients without steroid medication [OR: 2.202; 95% CI: 1.698-2.856, p < 0.001]. To our knowledge, no meta-analysis has evaluated the effect of steroid and anti-TNFα treatment in IBD patients. The major strength of our meta-analysis is the inclusion of large numbers of IBD patients with VTE events analysed at once, which would imply difficulties in randomized controlled trials. Thromboembolism is one of the extraintestinal manifestations in IBD. The prevalence and incidence rate of VTE in IBD are 1.2-6.7% and 6.3 per 1000 person-years in clinical studies, respectively. 15, 41, 42 DVT and PE are the most common types of VTE in IBD, but thromboses may also occur at unusual sites such as in cerebrovascular, retinal, portal, mesenteric, splenic or internal jugular veins. 42, 43 The association between VTE and disease activity has been well established; at the time of a flare-up, the increase in VTE risk is more prominent.
14 Other disease-specific risk factors, which have been identified in several studies, include colonic disease, fistulizing or stenotizing behaviour and surgical treatment. 16, 44 Recent literature indicates that drugs used in IBD treatment could also be considered as potential contributors to VTE pathogenesis. Systemic corticosteroids and anti-TNFα agents are both potent anti-inflammatory drugs used in moderately and severely active IBD flare-ups.
Steroids, however, have an independent thrombogenic effect from inflammatory processes. It has been shown that exogenous, systemic glucocorticoids and also excess endogenous cortisol [e.g. Cushing's syndrome] are linked to VTE risk. 45, 46 Hypercoagulability in Cushing's syndrome is due to increased production of procoagulant factors with activation of the coagulation cascade and an impaired fibrinolytic capacity. 46 Additionally, the risk of VTE is increased among glucocorticoid users in non-IBD populations [for systemic glucocorticoids, adjusted incidence rate ratio (IRR) is 2.31, 95% CI: 2.18-2.45], and this becomes more prominent at high doses. 45, 47 Corticosteroids administered to healthy volunteers also increase clotting factor levels and fibrinogen, which may also be related to the increased risk of thrombosis in the absence of inflammation. 48 TNFα is a proinflammatory cytokine which has been reported to link inflammation and thrombosis in IBD. The findings of Yoshida et al. implicate TNFα in the enhanced microvascular thrombosis in dextran sodium sulphate-induced colitis model, and suggest that the action of TNFα accounts for most of the colitis-enhanced thrombotic response. 49 Therefore, patients receiving anti-TNFα agents potentially have a decreased risk for thromboembolic complications. In addition to neutralizing TNFα, infliximab treatment in CD significantly reduced plasma soluble CD40L inflammatory cytokine levels, which might also decrease the risk of VTE. 50 During our meta-analysis search, only three studies were found assessing VTE risk in IBD patients treated with anti-TNFα agents. deFonseka et al. reported that the VTE risk is significantly lower when using TNFα inhibitor therapy in hospitalized IBD patients, 28 whereas systemic corticosteroids were associated with an increased risk. In addition, use of anti-TNFα medication lowered the risk of post-hospitalization VTE in a greater Boston cohort. 33 Higgins et al. showed that biologics monotherapy resulted in a 5-fold reduction in VTE risk compared with patients receiving corticosteroid treatment. 34 Moreover, this association between steroids and VTE risk seems to be dose-dependent. 34 The study of Higgins et al. showed not only that the inflammatory effect itself is responsible for the elevated VTE risk in IBD but also that the corticosteroid drugs themselves increase VTE risk. 34 Several limitations of this meta-analysis must be considered. The first is the quality of data. All the included studies have a retrospective design, the data were extracted from medical records so patients were not randomized, and unrecognized confounding factors could bias our results and weaken the conclusions. At least four relevant studies were excluded due to unavailable ORs of VTE risk. 42, 51, 52 In the study of Scoville et al., 53 there were non-IBD VTE controls as comparators for VTE risk in IBD, which did not match the control group criteria in our meta-analysis. Additionally, we cannot rule out that we lost relevant articles by having imposed English language, as a filter, on the search.
Secondly, there was substantial heterogeneity across the studies selected in subgroup A [I 2 = 66.97]. Very different types of studies were included; some studies are population-based cohorts, while other data were derived from postoperative settings or hospitalized patients. However, the duration of follow-up was almost equal in the majority of the included studies. Likewise, there may be variability in disease phenotype of IBD among patients. Although colonic disease and disease extension correlate with VTE risk, 16 the articles included no information on disease location or disease characteristics, so we were unable to analyse this parameter.
Thirdly, there were no quantitative activity indices for both UC and CD available in the publications, although the use of steroids and biologics indicates moderate to severe disease course. Thus, we could not evaluate the effect of the exact severity of the disease and the effect of consecutive immobilization on thromboembolic risk.
In addition, we do not know how many IBD patients were given pharmacological thromboprophylaxis in the studies. Only two of the included studies report on the use of VTE prophylaxis, in which the use of thromboembolic prophylaxis based on hospital protocols was associated with reduced VTE risk. 28, 33 However, it is of note that the publication year of all trials is mainly before the implementation of VTE guidelines and consensus statements. 41, 54 Finally, if pharmacokinetic measurements had been used in the studies, it would have been possible to determine the plausible effect of drug levels and anti-drug antibodies on VTE risk.
In summary, the present meta-analysis confirms that corticosteroid use in IBD patients carries a 2-fold risk of VTE. In contrast, thromboembolic risk decreases when using anti-TNFα agents for active disease instead of steroids. These associations highlight the importance of steroid-sparing therapy in IBD, especially in patients with additional risk factors for VTE. The choice between glucocorticoids and anti-TNFα therapy in the management of severe flare-ups should take this into consideration, especially in patients with previous VTE or a family history of thrombotic events.
According to recent guidelines, anticoagulant prophylaxis should be considered in all hospitalized and outpatients with severe IBD. 41, 54, 55 Anticoagulant thromboprophylaxis is recommended with low-molecular-weight heparin, low-dose unfractioned heparin or fondaparinux. 41 Recently, a risk assessment algorithm for IBD patients at risk of developing VTE has been proposed. 56 Patients with IBD should be stratified according to their general and IBDspecific risk factors for VTE into high-risk and intermediate/lowrisk patients. In addition to a detailed patient history focused on well-known general and disease-specific VTE risk factors, clot lysis parameters should be included in the risk assessment. 56 We recognize the importance of our findings in the promotion of the appropriate thromboprophylaxis during steroid treatment. Further research is needed to establish the exact weight of these factors and large prospective cohort studies are awaited. 
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